Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

RCT (n=668) found that ribociclib + letrozole resulted in a longer progression free survival vs letrozole + placebo (63.0% vs 42.2% at 18 months, HR 0.56, 95% CI 0.43-0.72). In patients with measurable disease at baseline the overall response rate was 52.7% vs 37.1% (p<0.001).